Ho, Won Jin https://orcid.org/0000-0003-2644-5086
Sharma, Gaurav
Zhu, Qingfeng
Stein-O'Brien, Genevieve
Durham, Jennifer
Anders, Robert
Popovic, Aleksandra
Mo, Guanglan
Kamel, Ihab
Weiss, Matthew
Jaffee, Elizabeth
Fertig, Elana J
Yarchoan, Mark
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/gutjnl-2020-320716
1215 Spatial profiling identifies antigen-presenting CAFs as potential mediators of response to neoadjuvant immunotherapy in hepatocellular carcinoma
https://doi.org/10.1136/jitc-2025-sitc2025.1215
Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy
https://doi.org/10.1136/jitc-2020-000932
641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma
https://doi.org/10.1136/jitc-2023-sitc2023.0641
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Funding for this research was provided by:
National Cancer Institute (P30 CA006973, P50 CA062924)
Emerson Collective Cancer Research Fund (640183)